[(2R)-3-[(2R)-2-amino-3-[[(2S,5S)-9-amino-5-[2-[(2S)-6-amino-1-oxo-1-[[(5S,8S)-1,8,12-triamino-6,7-dioxododecan-5-yl]amino]hexan-2-yl]hydrazinyl]-1-hydroxy-3,4-dioxononan-2-yl]amino]-3-oxopropyl]sulfanyl-2-hexadecanoyloxypropyl] hexadecanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2R)-3-[(2R)-2-amino-3-[[(2S,5S)-9-amino-5-[2-[(2S)-6-amino-1-oxo-1-[[(5S,8S)-1,8,12-triamino-6,7-dioxododecan-5-yl]amino]hexan-2-yl]hydrazinyl]-1-hydroxy-3,4-dioxononan-2-yl]amino]-3-oxopropyl]sulfanyl-2-hexadecanoyloxypropyl] hexadecanoate
• 化学式: C₆₅H₁₂₆N₁₀O₁₁S
• 分子量: 1255.8
• InChiKey: FZMIHEJCASVVDG-GHYFRYPYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.4
• 重原子数：
  87
• 可旋转键数：
  67
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  405
• 氢给体数：
  11
• 氢受体数：
  20

文献信息

• WT1 PEPTIDE CANCER VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION
  申请人：OSAKA UNIVERSITY

  公开号：US20140220055A1

  公开（公告）日：2014-08-07

  The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.
• VACCINE COMPOSITION FOR TRANSDERMAL ADMINISTRATION
  申请人：NITTO DENKO CORPORATION

  公开号：US20140220100A1

  公开（公告）日：2014-08-07

  The invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity comprising (i) HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.
• VACCINE COMPOSITION
  申请人：NITTO DENKO CORPORATION

  公开号：US20140220063A1

  公开（公告）日：2014-08-07

  The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter.
• VACCINE COMPOSITION FOR MUCOSAL ADMINISTRATION
  申请人：NITTO DENKO CORPORATION

  公开号：US20140220079A1

  公开（公告）日：2014-08-07

  The present invention provides a cancer vaccine composition for mucosal administration comprising (i) a HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.
• TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION
  申请人：Osaka University

  公开号：US20140220105A1

  公开（公告）日：2014-08-07

  The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising: a support, an adhesive layer comprising an adhesive disposed on one side of the support, wherein the adhesive layer carries a combination of: (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy.